Pig-to-non-human primate heart transplantation: The final step toward clinical xenotransplantation?

costimulation blockade graft growth heart preservation orthotopic heart transplantation xenotransplantation

Journal

The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation
ISSN: 1557-3117
Titre abrégé: J Heart Lung Transplant
Pays: United States
ID NLM: 9102703

Informations de publication

Date de publication:
08 2020
Historique:
received: 19 02 2020
revised: 25 04 2020
accepted: 10 05 2020
pubmed: 13 6 2020
medline: 22 7 2021
entrez: 13 6 2020
Statut: ppublish

Résumé

The demand for donated human hearts far exceeds the number available. Xenotransplantation of genetically modified porcine organs provides an alternative. In 2000, an Advisory Board of the International Society for Heart and Lung Transplantation set the benchmark for commencing clinical cardiac xenotransplantation as consistent 60% survival of non-human primates after life-supporting porcine heart transplantations. Recently, we reported the stepwise optimization of pig-to-baboon orthotopic cardiac xenotransplantation finally resulting in consistent success, with 4 recipients surviving 90 (n = 2), 182, and 195 days. Here, we report on 4 additional recipients, supporting the efficacy of our procedure. The first 2 additional recipients succumbed to porcine cytomegalovirus (PCMV) infections on Days 15 and 27, respectively. In 2 further experiments, PCMV infections were successfully avoided, and 3-months survival was achieved. Throughout all the long-term experiments, heart, liver, and renal functions remained within normal ranges. Post-mortem cardiac diameters were slightly increased when compared with that at the time of transplantation but with no detrimental effect. There were no signs of thrombotic microangiopathy. The current regimen enabled the prolonged survival and function of orthotopic cardiac xenografts in altogether 6 of 8 baboons, of which 4 were now added. These results exceed the threshold set by the Advisory Board of the International Society for Heart and Lung Transplantation. The results of our current and previous experimental cardiac xenotransplantations together fulfill for the first time the pre-clinical efficacy suggestions. PCMV-positive donor animals must be avoided.

Sections du résumé

BACKGROUND
The demand for donated human hearts far exceeds the number available. Xenotransplantation of genetically modified porcine organs provides an alternative. In 2000, an Advisory Board of the International Society for Heart and Lung Transplantation set the benchmark for commencing clinical cardiac xenotransplantation as consistent 60% survival of non-human primates after life-supporting porcine heart transplantations. Recently, we reported the stepwise optimization of pig-to-baboon orthotopic cardiac xenotransplantation finally resulting in consistent success, with 4 recipients surviving 90 (n = 2), 182, and 195 days. Here, we report on 4 additional recipients, supporting the efficacy of our procedure.
RESULTS
The first 2 additional recipients succumbed to porcine cytomegalovirus (PCMV) infections on Days 15 and 27, respectively. In 2 further experiments, PCMV infections were successfully avoided, and 3-months survival was achieved. Throughout all the long-term experiments, heart, liver, and renal functions remained within normal ranges. Post-mortem cardiac diameters were slightly increased when compared with that at the time of transplantation but with no detrimental effect. There were no signs of thrombotic microangiopathy. The current regimen enabled the prolonged survival and function of orthotopic cardiac xenografts in altogether 6 of 8 baboons, of which 4 were now added. These results exceed the threshold set by the Advisory Board of the International Society for Heart and Lung Transplantation.
CONCLUSIONS
The results of our current and previous experimental cardiac xenotransplantations together fulfill for the first time the pre-clinical efficacy suggestions. PCMV-positive donor animals must be avoided.

Identifiants

pubmed: 32527674
pii: S1053-2498(20)31556-4
doi: 10.1016/j.healun.2020.05.004
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

751-757

Commentaires et corrections

Type : CommentIn
Type : CommentIn

Informations de copyright

Copyright © 2020. Published by Elsevier Inc.

Auteurs

Bruno Reichart (B)

Transregional Collaborative Research Center, Walter Brendel Center of Experimental Medicine, LMU Munich, Munich, Germany. Electronic address: bruno.reichart@med.uni-muenchen.de.

Matthias Längin (M)

Department of Anaesthesiology, University Hospital, LMU Munich, Munich, Germany.

Julia Radan (J)

Transregional Collaborative Research Center, Walter Brendel Center of Experimental Medicine, LMU Munich, Munich, Germany.

Maren Mokelke (M)

Transregional Collaborative Research Center, Walter Brendel Center of Experimental Medicine, LMU Munich, Munich, Germany.

Ines Buttgereit (I)

Transregional Collaborative Research Center, Walter Brendel Center of Experimental Medicine, LMU Munich, Munich, Germany.

Jiawei Ying (J)

Transregional Collaborative Research Center, Walter Brendel Center of Experimental Medicine, LMU Munich, Munich, Germany.

Ann Kathrin Fresch (AK)

Transregional Collaborative Research Center, Walter Brendel Center of Experimental Medicine, LMU Munich, Munich, Germany.

Tanja Mayr (T)

Department of Anaesthesiology, University Hospital, LMU Munich, Munich, Germany.

Lara Issl (L)

Transregional Collaborative Research Center, Walter Brendel Center of Experimental Medicine, LMU Munich, Munich, Germany.

Stefan Buchholz (S)

Department of Cardiac Surgery, University Hospital, LMU Munich, Munich, Germany.

Sebastian Michel (S)

Department of Cardiac Surgery, University Hospital, LMU Munich, Munich, Germany.

Reinhard Ellgass (R)

Department of Cardiac Surgery, University Hospital, LMU Munich, Munich, Germany.

Maks Mihalj (M)

Department of Cardiovascular Surgery, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.

Stefanie Egerer (S)

Gene Center, Institute of Molecular Animal Breeding and Biotechnology, LMU Munich, Munich, Germany.

Andrea Baehr (A)

Gene Center, Institute of Molecular Animal Breeding and Biotechnology, LMU Munich, Munich, Germany.

Barbara Kessler (B)

Gene Center, Institute of Molecular Animal Breeding and Biotechnology, LMU Munich, Munich, Germany.

Elisabeth Kemter (E)

Gene Center, Institute of Molecular Animal Breeding and Biotechnology, LMU Munich, Munich, Germany.

Mayuko Kurome (M)

Gene Center, Institute of Molecular Animal Breeding and Biotechnology, LMU Munich, Munich, Germany.

Valeri Zakhartchenko (V)

Gene Center, Institute of Molecular Animal Breeding and Biotechnology, LMU Munich, Munich, Germany.

Stig Steen (S)

Department of Cardiothoracic Surgery, Lunds University and Skåne University Hospital, Lund, Sweden.

Trygve Sjöberg (T)

Department of Cardiothoracic Surgery, Lunds University and Skåne University Hospital, Lund, Sweden.

Audrius Paskevicius (A)

Department of Cardiothoracic Surgery, Lunds University and Skåne University Hospital, Lund, Sweden.

Luise Krüger (L)

Robert Koch Institute, Berlin, Germany.

Uwe Fiebig (U)

Robert Koch Institute, Berlin, Germany.

Joachim Denner (J)

Robert Koch Institute, Berlin, Germany.

Antonia W Godehardt (AW)

Division of Medical Biotechnology, Paul-Ehrlich-Institut, Langen, Germany.

Ralf R Tönjes (RR)

Division of Medical Biotechnology, Paul-Ehrlich-Institut, Langen, Germany.

Anastasia Milusev (A)

Department for BioMedical Research, University of Bern, Bern, Switzerland.

Robert Rieben (R)

Department for BioMedical Research, University of Bern, Bern, Switzerland.

Riccardo Sfriso (R)

Department for BioMedical Research, University of Bern, Bern, Switzerland.

Christoph Walz (C)

Institute of Pathology, Faculty of Medicine, LMU Munich, Munich, Germany.

Thomas Kirchner (T)

Institute of Pathology, Faculty of Medicine, LMU Munich, Munich, Germany.

David Ayares (D)

Revivicor, Blacksburg, Virginia.

Karen Lampe (K)

German Primate Center, Göttingen, Germany.

Uwe Schönmann (U)

German Primate Center, Göttingen, Germany.

Christian Hagl (C)

Department of Cardiac Surgery, University Hospital, LMU Munich, Munich, Germany.

Eckhard Wolf (E)

Gene Center, Institute of Molecular Animal Breeding and Biotechnology, LMU Munich, Munich, Germany.

Nikolai Klymiuk (N)

Gene Center, Institute of Molecular Animal Breeding and Biotechnology, LMU Munich, Munich, Germany.

Jan-Michael Abicht (JM)

Department of Anaesthesiology, University Hospital, LMU Munich, Munich, Germany.

Paolo Brenner (P)

Department of Cardiac Surgery, University Hospital, LMU Munich, Munich, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH